Nurix Therapeutics Inc. (NRIX)
Nurix Therapeutics Statistics
Share Statistics
Nurix Therapeutics has 75.89M shares outstanding. The number of shares has increased by 17.92% in one year.
| Shares Outstanding | 75.89M |
| Shares Change (YoY) | 17.92% |
| Shares Change (QoQ) | 7.13% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 74.72M |
| Failed to Deliver (FTD) Shares | 14.24K |
| FTD / Avg. Volume | 1.55% |
Short Selling Information
The latest short interest is 12.16M, so 15.95% of the outstanding shares have been sold short.
| Short Interest | 12.16M |
| Short % of Shares Out | 15.95% |
| Short % of Float | 18.75% |
| Short Ratio (days to cover) | 12.18 |
Valuation Ratios
The PE ratio is -7.67 and the forward PE ratio is -3.02. Nurix Therapeutics's PEG ratio is -0.88.
| PE Ratio | -7.67 |
| Forward PE | -3.02 |
| PS Ratio | 27.21 |
| Forward PS | 1.7 |
| PB Ratio | 2.82 |
| P/FCF Ratio | -8.16 |
| PEG Ratio | -0.88 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Nurix Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.46, with a Debt / Equity ratio of 0.05.
| Current Ratio | 6.46 |
| Quick Ratio | 6.46 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.16 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $190.73K |
| Profits Per Employee | $-676.81K |
| Employee Count | 286 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 270K |
| Effective Tax Rate | -0.14% |
Stock Price Statistics
The stock price has increased by -22.24% in the last 52 weeks. The beta is 2.24, so Nurix Therapeutics's price volatility has been higher than the market average.
| Beta | 2.24 |
| 52-Week Price Change | -22.24% |
| 50-Day Moving Average | 13.54 |
| 200-Day Moving Average | 20.1 |
| Relative Strength Index (RSI) | 42.71 |
| Average Volume (20 Days) | 920.91K |
Income Statement
In the last 12 months, Nurix Therapeutics had revenue of 54.55M and earned -193.57M in profits. Earnings per share was -2.88.
| Revenue | 54.55M |
| Gross Profit | 54.55M |
| Operating Income | -213.03M |
| Net Income | -193.57M |
| EBITDA | -213.03M |
| EBIT | -213.03M |
| Earnings Per Share (EPS) | -2.88 |
Balance Sheet
The company has 110M in cash and 28.3M in debt, giving a net cash position of 81.69M.
| Cash & Cash Equivalents | 110M |
| Total Debt | 28.3M |
| Net Cash | 81.69M |
| Retained Earnings | -738.77M |
| Total Assets | 615.04M |
| Working Capital | 473.71M |
Cash Flow
In the last 12 months, operating cash flow was -172.58M and capital expenditures -9.27M, giving a free cash flow of -181.86M.
| Operating Cash Flow | -172.58M |
| Capital Expenditures | -9.27M |
| Free Cash Flow | -181.86M |
| FCF Per Share | -2.71 |
Margins
Gross margin is 100%, with operating and profit margins of -390.52% and -354.85%.
| Gross Margin | 100% |
| Operating Margin | -390.52% |
| Pretax Margin | -354.36% |
| Profit Margin | -354.85% |
| EBITDA Margin | -390.52% |
| EBIT Margin | -390.52% |
| FCF Margin | -333.38% |
Dividends & Yields
NRIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NRIX is $31, which is 193.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $31 |
| Price Target Difference | 193.6% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
Scores
| Altman Z-Score | 1.44 |
| Piotroski F-Score | 4 |